drugset / Trial / NCT01423955

Erythropoietin (EPO) to Protect Renal Function After Cardiac Surgery

NCT01423955 ↗

Phase 2 Completed 75 enrolled Region Skane
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate the potential of erythropoietin in reducing risk and degree of acute kidney injury after cardiac surgery.

Timeline

Start
2011-10
Primary completion
2013-01
Completion
2013-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Erythropoietin zeta Unknown 400 iu/kg —

Indications